Inhibrx claims first win for long-sought immunotherapy target
📍 How it ended
Inhibrx reported Phase 2 data for INBRX‑106 that nearly doubled the response rate and showed an interim median progression‑free survival of 9.6 months, prompting the company to claim a first win for its OX40 agonist and the CEO to tout the durability of the results. Coverage then fell quiet without further reported resolution.
Epilogue added 49d ago, after coverage quieted.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: Coverage escalated across 9 distinct news outlets with 10 published articles, achieving a live velocity of 8.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Inhibrx claims first win for long-sought immunotherapy target" developed substantial multi-source reporting across the Business sector, tracked across 9 distinct newsrooms by Newsylist.
Key reporting was led by Investing.com, Seeking Alpha, PR Newswire and Stock Titan. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 49d ago.
Coverage (10)
-
-
-
-
-
-
-
-
-
-
Inhibrx claims first win for long-sought immunotherapy target STAT · 62d ago broke it first
Questions people are asking
What drove coverage for Inhibrx claims first win for long-sought immunotherapy target?
Coverage spiked when 9 independent newsrooms published 10 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.